CorMedix Inc.
- CRMD
- NASDAQ
- Biotechnology
- Anti-Infective Therapeutics
- Catheter-Related Infection Treatment
$7.38
Today +1.65%Quote Oct 19, 2026, 08:00 PM UTC
−4.40%over the last month
Max drawdown −9.3%From 1-month high −6.9%3 months −9.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About CorMedix
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution.
Where the money comes from
Q2 2026 revenue $101.9M
- Product$94.3M92.6%
- Contract Revenue$5.0M4.9%
- Grant Income$2.6M2.6%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
191
Founded
2006
Market value
$575.2M
Quote Oct 19
Floor
$7.37
0.1% below price
Resistance
$7.62
3.2% above price
Price vs analyst targets
8 analysts
Lowest target
$14.00Highest target
$15.00
$14.00Highest target
$15.00
- Price $7.38
- Average target $14.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 96% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CRMDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free